Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: billkirn who wrote (199)	1/21/1997 3:17:00 AM
From: John Grandy	of 6136

<< The entry criteria for the study include CD4 cells (greater than or equal to) 200/mm3 and plasma HIV RNA (greater than or equal to) 20,000 copies per mL. >> does this mean that double PI treatment is not appropriate for people with CD4 less than 200/mm3. what treatment(s) are used on those people?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next